Entropy Neurodynamics has partnered with BioCina to establish GMP manufacturing for its intravenous psilocin formulation TRP-8803, a critical step toward late-stage clinical trials and commercialisation.
- Development and Manufacturing Services Agreement with BioCina
- GMP manufacture of proprietary IV-infused psilocin TRP-8803
- Manufacturing to support late-stage clinical trials and regulatory submissions
- BioCina’s Perth facility to produce sterile vials using robotic aseptic filling
- Agreement underpins scalable global supply and multi-indication development
Strategic Manufacturing Partnership Established
Entropy Neurodynamics Limited (ASX:ENP) has taken a significant step in advancing its psychedelic therapy pipeline by signing a Development and Manufacturing Services Agreement with BioCina, a leading contract development and manufacturing organisation (CDMO). This partnership secures Good Manufacturing Practice (GMP) production capabilities for Entropy’s proprietary intravenous psilocin formulation, TRP-8803, positioning the company to support its expanding clinical program and future commercial ambitions.
BioCina’s Role and Capabilities
BioCina brings extensive expertise in aseptic fill-finish and sterile injectable manufacturing, operating a TGA-licensed facility in Perth that complies with FDA inspections and EMA-aligned quality systems. The company’s infrastructure includes a Cytiva SA25 robotic aseptic filling line, which will be used to produce TRP-8803 in sterile 10 mL glass vials. With over 225 million sterile units manufactured annually and a global supply footprint spanning more than 140 countries, BioCina is well-equipped to meet the regulatory and scale demands of Entropy’s clinical and commercial plans.
Supporting Clinical Development and Regulatory Strategy
The agreement encompasses a comprehensive manufacturing program, including analytical verification, engineering batch production, and GMP manufacture of both placebo and active drug product batches. The resulting pharmaceutical and stability data will underpin Entropy’s regulatory submissions across the United States, Europe, and other key markets. This manufacturing foundation is essential as TRP-8803 progresses through Phase 2/3 trials, including a recently approved 72-patient study targeting eight neuropsychiatric indications with high unmet clinical need.
Advancing a Precision-Controlled Psychedelic Therapy
TRP-8803 is designed to address the limitations of oral psilocybin by enabling precise control over the onset, intensity, and duration of the psychedelic experience through intravenous infusion. This approach aims to deliver consistent therapeutic exposure and a reproducible treatment profile suitable for large-scale clinical deployment. The scalable manufacturing process developed with BioCina will support this vision, ensuring product consistency and rapid scale-up capabilities as clinical evidence accumulates.
Management Perspectives on the Partnership
BioCina CEO Dr Thomas Broudy emphasised the company’s readiness to support Entropy’s innovative pharmaceutical product through clinical development and commercialisation, highlighting BioCina’s established sterile manufacturing infrastructure and global supply capabilities. Entropy CEO Jason Carroll described the agreement as a strategic milestone that builds the necessary infrastructure to realise TRP-8803’s broader potential across multiple indications and geographies. Carroll underscored the importance of aligning manufacturing capabilities with the expanding clinical evidence base to position TRP-8803 as a globally relevant therapeutic platform.
Bottom Line?
Securing GMP manufacturing with BioCina lays the groundwork for Entropy’s TRP-8803 to advance through pivotal trials and scale globally, but clinical and regulatory hurdles remain ahead.
Questions in the middle?
- How will manufacturing scale align with the timing of Phase 2/3 clinical trial readouts?
- What regulatory challenges might arise in different international markets given the controlled substance status of psilocin?
- Could this manufacturing partnership facilitate future collaborations or licensing deals for TRP-8803?